Tripathi Siddhant, Sharma Yashika, Kumar Dileep
Poona College of Pharmacy, Bharati Vidyapeeth (Deemed to be) University, Pune, Maharashtra, 411038, India.
Department of Pharm Chemistry, Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education, Manipal, Karnataka, 576104, India.
Rev Recent Clin Trials. 2025;20(2):124-141. doi: 10.2174/0115748871330861241030143321.
Alzheimer's disease (AD) is a multidimensional, complex condition that affects individuals all over the world. Despite decades of experimental and clinical research that has revealed various processes, many concerns concerning the origin of Alzheimer's disease remain unresolved. Despite the notion that there isn't a complete set of jigsaw pieces, the growing number of public data-sharing initiatives that collect biological, clinical, and lifestyle data from those suffering from Alzheimer's disease has resulted in virtually endless volumes of knowledge about the disorder, far beyond what humans can comprehend. Furthermore, combining Big Data from multi- -omics research gives a chance to investigate the pathophysiological processes underlying the whole biological spectrum of Alzheimer's disease. To improve knowledge on the subject of Alzheimer's disease, Artificial Intelligence (AI) offers a wide variety of approaches for evaluating complex and significant data. The introduction of next-generation sequencing and microarray technologies has resulted in significant growth in genetic data research. When it comes to assessing such complex projects, AI technology beats conventional statistical techniques of data processing. This review focuses on current research and potential challenges for AI in Alzheimer's disease research. This article, in particular, examines how AI may assist healthcare practitioners with patient stratification, estimating an individual's chance of AD conversion, and diagnosing AD using computer-aided diagnostic methodologies. Ultimately, scientists want to develop individualized, efficient medicines.
阿尔茨海默病(AD)是一种影响全球个体的多维度复杂病症。尽管数十年的实验和临床研究揭示了各种过程,但许多关于阿尔茨海默病起源的问题仍未得到解决。尽管还没有一套完整的拼图碎片,但越来越多的公共数据共享倡议从阿尔茨海默病患者那里收集生物、临床和生活方式数据,这带来了几乎无穷无尽的关于该病症的知识,远远超出了人类的理解范围。此外,整合来自多组学研究的大数据为研究阿尔茨海默病整个生物学谱背后的病理生理过程提供了机会。为了增进对阿尔茨海默病这一主题的了解,人工智能(AI)提供了多种评估复杂且重要数据的方法。下一代测序和微阵列技术的引入使得基因数据研究有了显著增长。在评估此类复杂项目时,人工智能技术优于传统的数据处理统计技术。本综述聚焦于人工智能在阿尔茨海默病研究中的当前研究及潜在挑战。特别是本文探讨了人工智能如何通过计算机辅助诊断方法帮助医疗从业者进行患者分层、估计个体患AD转化的可能性以及诊断AD。最终,科学家们希望开发出个性化、高效的药物。